NO20063326L - Kombinasjon av (a) N-{5-[4-(4-metyl-piperazinometyl)-benzoylamid]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og (b) minst en hypusineringsinhibitor og anvendelse derav - Google Patents

Kombinasjon av (a) N-{5-[4-(4-metyl-piperazinometyl)-benzoylamid]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og (b) minst en hypusineringsinhibitor og anvendelse derav

Info

Publication number
NO20063326L
NO20063326L NO20063326A NO20063326A NO20063326L NO 20063326 L NO20063326 L NO 20063326L NO 20063326 A NO20063326 A NO 20063326A NO 20063326 A NO20063326 A NO 20063326A NO 20063326 L NO20063326 L NO 20063326L
Authority
NO
Norway
Prior art keywords
combination
pyrimidinamine
methylphenyl
pyridyl
inhibitor
Prior art date
Application number
NO20063326A
Other languages
English (en)
Norwegian (no)
Inventor
Tim H Bruemmendorf
Stefan Balabanov
Ulrike Hartmann
Winfried Kammer
Alfred Nordheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20063326L publication Critical patent/NO20063326L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20063326A 2003-12-19 2006-07-18 Kombinasjon av (a) N-{5-[4-(4-metyl-piperazinometyl)-benzoylamid]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og (b) minst en hypusineringsinhibitor og anvendelse derav NO20063326L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53156303P 2003-12-19 2003-12-19
PCT/EP2004/014439 WO2005058320A1 (en) 2003-12-19 2004-12-17 COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF

Publications (1)

Publication Number Publication Date
NO20063326L true NO20063326L (no) 2006-09-19

Family

ID=34700180

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063326A NO20063326L (no) 2003-12-19 2006-07-18 Kombinasjon av (a) N-{5-[4-(4-metyl-piperazinometyl)-benzoylamid]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og (b) minst en hypusineringsinhibitor og anvendelse derav

Country Status (17)

Country Link
US (1) US20080139480A1 (de)
EP (1) EP1696917A1 (de)
JP (1) JP2007514699A (de)
KR (1) KR20060125810A (de)
CN (1) CN1889952A (de)
AU (2) AU2004298761A1 (de)
BR (1) BRPI0417759A (de)
CA (1) CA2547196A1 (de)
EC (1) ECSP066656A (de)
IL (1) IL176070A0 (de)
MA (1) MA28240A1 (de)
MX (1) MXPA06006925A (de)
NO (1) NO20063326L (de)
RU (1) RU2006125741A (de)
TN (1) TNSN06182A1 (de)
WO (1) WO2005058320A1 (de)
ZA (1) ZA200603904B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197440B1 (de) 2007-08-31 2012-12-26 Janssen Pharmaceutica, N.V. Kombinationen von imazalil und hydroxypyridonen
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
EP2242365B1 (de) 2008-02-06 2013-01-16 Janssen Pharmaceutica NV Kombinationen von pyrimethanil und pyrionverbindungen
US8043422B2 (en) 2008-02-06 2011-10-25 Janssen Pharmaceutica, Nv Combinations of phenylpyrroles and pyrion compounds
US20110212176A1 (en) * 2008-10-31 2011-09-01 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
WO2011153197A1 (en) * 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
EP2585063A1 (de) * 2010-06-01 2013-05-01 Biotheryx Inc. Verfahren zur behandlung von hämatologischen malignomen mit 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridon
AR082181A1 (es) 2010-06-10 2012-11-21 Janssen Pharmaceutica Nv Combinaciones de pirimetanil y monoterpenos
US9237749B2 (en) 2010-07-01 2016-01-19 Janssen Pharmaceutica N.V. Antimicrobial combinations of pyrion compounds with polyethyleneimines
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227593A1 (de) * 1985-11-25 1987-07-01 The Hospital For Sick Children Verwendung von Chelationsmitteln
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
DE60233315D1 (de) * 2001-03-23 2009-09-24 Enzon Inc Prodrugs von krebsmitteln mit substituierten aromatischen säuren
WO2004007676A2 (en) * 2002-07-15 2004-01-22 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms

Also Published As

Publication number Publication date
AU2004298761A1 (en) 2005-06-30
AU2009201694A1 (en) 2009-05-28
CA2547196A1 (en) 2005-06-30
WO2005058320A1 (en) 2005-06-30
EP1696917A1 (de) 2006-09-06
KR20060125810A (ko) 2006-12-06
MA28240A1 (fr) 2006-10-02
MXPA06006925A (es) 2006-08-23
CN1889952A (zh) 2007-01-03
TNSN06182A1 (en) 2007-11-15
ZA200603904B (en) 2007-09-26
RU2006125741A (ru) 2008-01-27
IL176070A0 (en) 2006-10-05
US20080139480A1 (en) 2008-06-12
JP2007514699A (ja) 2007-06-07
ECSP066656A (es) 2006-10-25
BRPI0417759A (pt) 2007-04-10

Similar Documents

Publication Publication Date Title
NO20063326L (no) Kombinasjon av (a) N-{5-[4-(4-metyl-piperazinometyl)-benzoylamid]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og (b) minst en hypusineringsinhibitor og anvendelse derav
NO20076323L (no) Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metyl-fenyl}-4-(3-pyridyl)-2-pyrimidinamin og en aromataseinhibitor, anvendelse av kombinasjonen samt farmasøytisk preparat
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
MX2007006204A (es) Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
CY1112281T1 (el) Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
HUP0301512A2 (hu) Gyomor-bél csatornában fellépő kötőszöveti váz tumorok kezelése
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
NO20092398L (no) Krystallinske former av solvatisert ilaprazol
CY1105839T1 (el) 4-(4-μεθυλπιπepαζιν-1-υλμεθυλ)-ν-[4-μεθυλ-3-(4-πυριδιν-3-υλ)πυριμιδιν-2-υλ-αμινο)φαινυλ]-βενζαμιδη για τη θepαπεια αng ii - μεσολαβουμενων ασθενειων
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
AU2003259521A1 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
JP2006505582A5 (de)
HK1087638A1 (en) Use of tyrosine kinase inhibitors to treat diabetes
DK1503764T3 (da) 5-HT4-receptor-antagonister til behandling af hjertesvigt
ATE476183T1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
DE502005006028D1 (de) Homöpathisches mittel zur prophylaxe gegen von parasiten hervorgerufenen krankheiten
WO2006012958A3 (en) Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application